Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up
暂无分享,去创建一个
David Colquhoun | Stephen MacMahon | Andrew Tonkin | A. Keech | A. Tonkin | R. Simes | D. Hunt | S. MacMahon | D. Colquhoun | W. Hague | A. Kirby | P. Glasziou | Anthony C Keech | R. J. Simes | David M. Hunt | Adrienne Kirby | Paul Glasziou | P. Aylward | Wendy Hague | P. Aylward
[1] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.
[2] V. Fuster,et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. , 2000, Atherosclerosis.
[3] A. Keech,et al. Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: The ASPAC study , 2000 .
[4] M. Law,et al. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies , 1991, Cancer Causes & Control.
[5] H. White,et al. Cholesterol‐lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost‐effective? , 2002, The Medical journal of Australia.
[6] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[7] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[8] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[9] J. LeLorier,et al. Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.
[10] I. Marschner,et al. Long-term risk stratification for survivors of acute coronary syndromes - Results from the long-term intervention with pravastatin in ischemic disease (LIPID) study , 2001 .
[11] J. Gurwitz,et al. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? , 1999, Archives of internal medicine.
[12] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[13] R. Collins,et al. The MRC/BHF Heart Protection Study: preliminary results. , 2002, International journal of clinical practice.
[14] David Colquhoun,et al. Pravastatin Therapy and the Risk of Stroke , 2000 .
[15] C. Furberg,et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.
[16] S. Anand,et al. Cost of prevention. The case of lipid lowering. , 1996, Circulation.
[17] G. Thorgeirsson,et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.
[18] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[19] Philippe Amouyel,et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .
[20] B. Davis,et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. , 2002, European heart journal.
[21] Alan D. Lopez,et al. Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.
[22] J. Avorn,et al. Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.
[23] A. Keech,et al. Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project , 2000, Circulation.
[24] R. Rosenson,et al. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.
[25] J. Simons,et al. Apparent discontinuation rates in patients prescribed lipid‐lowering drugs , 1996, The Medical journal of Australia.